About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The Infection and Immunity in pediatric patients research group is a multidisciplinary pediatric research group made up of health professionals involved in translational research in the field of pediatric infectious diseases and immunodeficiencies, two related fields in terms of pathophysiology and clinical implications. It is a consolidated research group recognized by the AGAUR and is the only one with the accreditation of the Jeffrey Modell Foundation in research in the field of primary immunodeficiencies throughout the state.
The group was officially created in 2010, belongs to the area of Infectious Diseases and participates in the transversal programs of Advanced Translational Immunology and Rare Diseases and actively participates in national and international competitive projects, carries out multiple academic and industry-linked clinical trials and has increased the number and quality in recent years. In addition, it has its own laboratory specially dedicated to advanced immune studies.
PMID: 37882449 Journal: Future Oncology Year: 2023 Reference: Future Oncol. 2023 Oct 26. doi: 10.2217/fon-2023-0526. Impact factor: Publication type: Paper in international publication Authors: Agarwal, Neeraj; Alonso, Lucia; Azad, Arun A; Bordas, Anna; Casabona, Jordi; Chakrabarti, Jayeta; Chen, Hsiang-Chun; Colom-Cadena, Andreu; Fizazi, Karim; Ganem, Fabiana et al. DOI: 10.2217/fon-2023-0526
PMID: 37879817 Journal: Revista espanola de patologia Year: 2023 Reference: Rev Esp Patol. 2023 Oct-Dec;56(4):217-218. doi: 10.1016/j.patol.2023.09.001. Impact factor: Publication type: Editorial in national publication Authors: Acuna Perez, Maria Jose; Agueras, Cajal; Calavia, Olga; Colobran, Roger; Garcia Ramos, Maite; Garcia-Aznar, Jose Maria; Maneiro Pampin, Emilia; Minguell Domingo, Laura; Novoa Bolivar, Erika M; Ocejo Vinyals, Javier Gonzalo et al. DOI: 10.1016/j.patol.2023.09.001
PMID: 37922511 Journal: PEDIATRIC INFECTIOUS DISEASE JOURNAL Year: 2023 Reference: Pediatr Infect Dis J. 2023 Nov 3. doi: 10.1097/INF.0000000000004138. Impact factor: Publication type: Paper in international publication Authors: Beltran-Pavez, Carolina; Epalza, Cristina; Fortuny, Claudia; Frick, Marie Antoinette; Gonzalez-Alba, Jose Maria; Gutierrez-Lopez, Miguel; Holguin, Africa; Moreno, Santiago; Munoz Medina, Leopoldo; Navarro, Maria Luisa et al. DOI: 10.1097/INF.0000000000004138
PMID: 37925847 Journal: ESMO Open Year: 2023 Reference: ESMO Open. 2023 Nov 3;8(6):102059. doi: 10.1016/j.esmoop.2023.102059. Impact factor: Publication type: Other (letters to the editor, abstracts, corrigendum, etc.) Authors: Amaral, T; Beltran-Pavez, Carolina; Epalza, Cristina; Fortuny, Claudia; Frick, Marie Antoinette; Gonzalez-Alba, Jose Maria; Gutierrez-Lopez, Miguel; Holguin, Africa; Lambertini, M; Lim, K H J et al. DOI: 10.1016/j.esmoop.2023.102059
On European Antibiotic Awareness Day, we highlight the importance of using these medications responsibly and finding innovative solutions to combat this issue.
This appointment is an international recognition of VHIR's immunodeficiency research.
So far, 240 volunteers have been recruited within all the centres set to join adolescents’ clinical trial (named HH3) to test the efficacy, tolerability, and safety of the BIMERVAX® COVID-19 vaccine in adolescents aged 12 to 17.
